FDA authorizes Physio-Control to market LIFEPAK 20e defibrillator
The U.S. Food and Drug Administration has granted clearance to Physio-Control, Inc. for the commercialization of LIFEPAK 20e defibrillator/monitor in the United States. The device is an enhancement of the LIFEPAK 20. The new features include a stronger (Lithium-ion) battery and an on-screen fuel gauge. The novel version, also, is designed to facilitate easy transportation. This will help the hospitals to meet the standards set by Joint Commission for Accreditation of Healthcare Organizations to ensure the availability of resuscitation services in all the areas.
-
FDA Issues Class I Recall for Physio-Control’s LifePak 20/20e Defibrillators
Medtronic Fixing Defibrillator For Battery Issue
TomTec And Medis Launch Joint Cardiac Imaging And Analysis Product
St Jude And Hospitals To Pay Nearly $4 Million To Resolve Fraud Allegations
FDA approves market launch of Boston Scientific’s DES
